What is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Voyager Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst L. Nsongo forecasts that the company will post earnings per share of ($1.17) for the year. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share.

VYGR has been the topic of several other reports. Canaccord Genuity Group decreased their price target on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the stock an "overweight" rating in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $13.97.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $3.43 on Thursday. Voyager Therapeutics has a 1-year low of $2.75 and a 1-year high of $9.55. The stock's 50-day moving average is $3.54 and its 200 day moving average is $4.98. The company has a market cap of $189.50 million, a P/E ratio of 4.83 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million.

Insider Transactions at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This trade represents a 2.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.53% of the company's stock.

Institutional Trading of Voyager Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP increased its holdings in Voyager Therapeutics by 151.0% in the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock valued at $6,974,000 after buying an additional 740,000 shares during the period. Farallon Capital Management LLC lifted its stake in Voyager Therapeutics by 12.2% during the fourth quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock worth $14,576,000 after purchasing an additional 278,700 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Voyager Therapeutics by 24.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock worth $7,828,000 after acquiring an additional 275,571 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Voyager Therapeutics in the 4th quarter valued at about $746,000. Finally, ADAR1 Capital Management LLC grew its position in Voyager Therapeutics by 212.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company's stock worth $719,000 after purchasing an additional 86,158 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.